Trishula Therapeutics
TTX-030 | anti-CD39 antibody
- Headquarters
- South San Francisco, California
- Business Model
- B2B
- Website
- trishulatx.com
- Last Round
- Venture RoundAug 2020
- Rounds
- 1
About
Clinical-stage biotech developing TTX-030, a first-in-class anti-CD39 antibody for cancer immunotherapy.
Summary
Trishula Therapeutics is a Biotech company based in South San Francisco, United States. Its most recent funding was a Venture Round round in Aug 2020. Investors include MPM Capital, Canaan Partners and InterWest Partners.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2020
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...